Discover your next big idea for life sciences at PACK EXPO Las Vegas
Experience a breakthrough in life sciences packaging—explore solutions from 2,300 suppliers spanning all industries, all in one place this September.

Absorption Systems Receives U.S. Patent for IDAS2™, a Groundbreaking Test System for Fundamental Drug Properties

One-of-a-kind technology tests drug absorption and formulation performance in a single step.

This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.

Absorption Systems, a global leader in the science of translational medicine, announces the issuance of a U.S. patent for its unique In Vitro Dissolution Absorption System (IDAS2™) technology, which enables the simultaneous evaluation of drug dissolution and absorption in various dosage forms, including tablets, capsules, and pre-formulations. It is noteworthy that all claims in the patent application were granted, including both the device itself and the method of use. Industry demand for IDAS2 is already high, owing to its innovative design and integrated predictive ability.

With IDAS2, pharmaceutical scientists can now rapidly evaluate two fundamental properties of a finished drug product (tablet, capsule, etc.) at the same time: the dissolution rate, which is determined by the formulation (excipients) in which the active pharmaceutical ingredient (API) is packaged, and the absorption rate of the dissolved drug substance across a human intestinal cell monolayer, which is an intrinsic property of the API. And IDAS2 allows for the assessment of many formulations at the same time.

The ability to rapidly screen pre-formulations as well as finished oral dosage forms for both dissolution and permeability, simultaneously in an in vitro format, will improve the reliability of pre-clinical formulation testing, leading to better decisions concerning formulations that will advance to clinical testing in humans. Enhancing the predictive power of the system is the fact that IDAS2 includes the same human intestinal cells that Absorption Systems uses to classify drug permeability according to the Biopharmaceutics Classification System (BCS).

Dr. Jibin Li, co-inventor on the patent with Dr. Ismael J. Hidalgo, commented that "The patent for IDAS2 validates a lot of hard work over several years, from conception to prototype to finished product. It's very rewarding to see our efforts come to fruition in this way and to know that this technology will help get more effective and safer drugs to patients sooner."

Absorption Systems was well represented and participated in multiple scientific sessions at the recent Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists (AAPS) in Denver, CO.

For more information, please visit www.absorption.com.

Break out of the ordinary: see what’s new in life sciences packaging
At PACK EXPO Las Vegas, you’ll see machinery in action and new tech from 2,300 suppliers, collaborate with experts and explore transformative solutions. Join us in September to experience a breakthrough for life sciences products.
REGISTER NOW & SAVE!
Break out of the ordinary: see what’s new in life sciences packaging
List: Digitalization Companies From PACK EXPO
Looking for CPG-focused digital transformation solutions? Download our editor-curated list from PACK EXPO featuring top companies offering warehouse management, ERP, digital twin, and MES software with supply chain visibility and analytics capabilities—all tailored specifically for CPG operations.
Download Now
List: Digitalization Companies From PACK EXPO